Theravance Biopharma (TBPH) Convertible Debt (2016 - 2022)

Theravance Biopharma (TBPH) has 7 years of Convertible Debt data on file, last reported at $228.6 million in Q2 2022.

• Convertible Debt for Q2 2022 came in at $228.6 million, changed 0.47% year-over-year; the trailing twelve-month figure through Jun 2022 was $228.6 million (changed 0.47% YoY), and the FY2021 annual result was $228.0 million, changed 0.47% from the prior year.
• Convertible Debt held at $228.6 million in Q2 2022 per TBPH's latest filing, from $228.3 million in the prior quarter.
• Over five years, Convertible Debt peaked at $228.6 million in Q2 2022 and troughed at $224.0 million in Q1 2018.
• A 5-year average of $226.3 million and a median of $226.3 million in 2020 frame the typical range for Convertible Debt.
• The sharpest annual moves came in 2018 and 2022: Convertible Debt grew 0.48% in 2018, then climbed 0.47% in 2022.
• A 5-year view of Convertible Debt shows it stood at $224.8 million in 2018, then climbed by 0.48% to $225.9 million in 2019, then rose by 0.48% to $227.0 million in 2020, then increased by 0.47% to $228.0 million in 2021, then increased by 0.24% to $228.6 million in 2022.
• Business Quant data shows TBPH's Convertible Debt at $228.6 million in Q2 2022, $228.3 million in Q1 2022, and $228.0 million in Q4 2021.